help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2009-0270
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by de Lind van Wijngaarden, R. F. A.
Right arrow Articles by Hokken-Koelega, A. C. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lind van Wijngaarden, R. F. A.
Right arrow Articles by Hokken-Koelega, A. C. S.
Related Collections
Right arrow Neuroendocrinology and Pituitary
Right arrow Pediatric Endocrinology
Right arrow Calcium and Bone Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 94, No. 10 3763-3771
Copyright © 2009 by The Endocrine Society

Bone Mineral Density and Effects of Growth Hormone Treatment in Prepubertal Children with Prader-Willi Syndrome: A Randomized Controlled Trial

Roderick F. A. de Lind van Wijngaarden, Dederieke A. M. Festen, Barto J. Otten, Edgar G. A. H. van Mil, Joost Rotteveel, Roelof J. Odink, Mariëtte van Leeuwen, Danny A. J. P. Haring, Gianni Bocca, E. C. A. Mieke Houdijk and Anita C. S. Hokken-Koelega

Dutch Growth Research Foundation (R.F.A.d.L.v.W., D.A.M.F., A.C.S.H.-K.), 3016 AH Rotterdam, The Netherlands; Department of Pediatrics (R.F.A.d.L.v.W., D.A.M.F., A.C.S.H.-K.), Subdivision of Endocrinology, Erasmus University Medical Center Rotterdam, Sophia Children’s Hospital, 3015 GJ Rotterdam, The Netherlands; Department of Pediatrics (B.J.O.), Subdivision of Endocrinology, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands; Department of Pediatrics (E.G.A.H.v.M.), Hieronymus Bosch Medical Center, 5211 NL ‘s-Hertogenbosch, The Netherlands; Department of Pediatrics (J.R.), Subdivision of Endocrinology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands; Department of Pediatrics (R.J.O.), Catharina Hospital, 5623 EJ Eindhoven, The Netherlands; Department of Pediatrics (M.v.L.), St. Jansdal Hospital, 3844 DG Harderwijk, The Netherlands; Department of Pediatrics (D.A.J.P.H.), Diaconessenhuis, 2334 CK Leiden, The Netherlands; Department of Pediatrics (G.B.), Subdivision of Endocrinology, University Medical Center Groningen/Beatrix Children’s Hospital, 9713 GZ Groningen, The Netherlands; and Department of Pediatrics (E.C.A.M.H.), Subdivision of Endocrinology, Haga Hospitals/Juliana Children’s Hospital, 2566 MJ The Hague, The Netherlands

Address all correspondence and requests for reprints to: Roderick de Lind van Wijngaarden, Clinical Research Fellow, Dutch Growth Research Foundation, Erasmus University Medical Center/Sophia Children’s Hospital, Westzeedijk 106, 3016 AH Rotterdam, The Netherlands. E-mail: r.delindvanwijngaarden{at}erasmusmc.nl.

Background: Bone mineral density (BMD) is unknown in children with Prader-Willi syndrome (PWS), but is decreased in adults with PWS. In patients with GH deficiency, BMD increases during GH treatment.

Objectives: The aim of the study was to evaluate BMD in children with PWS and to study the effects of GH treatment.

Design: We conducted a randomized controlled GH trial. Forty-six prepubertal children were randomized into either a GH-treated group (1.0 mg/m2 · d) or a control group for 2 yr. At start, 6, 12, and 24 months of study, total body and lumbar spine BMD were measured by dual-energy x-ray absorptiometry, and lumbar spine bone mineral apparent density (BMAD) was calculated.

Results: Baseline total body and lumbar spine BMD SD score (SDS) were normal [mean (SD), –0.2 SDS (1.1) and –0.4 SDS (1.2), respectively]. BMADSDS, which corrects for short stature, was also normal [mean (SD), 0.40 SDS (1.1)]. Total body BMDSDS decreased during the first 6 months of GH (P < 0.0001), but increased during the second year of treatment. After 24 months of study, total body and lumbar spine BMDSDS, and the BMADSDS did not significantly differ between GH-treated children and randomized controls (P = 0.30, P = 0.44, and P = 0.47, respectively). Results were similar when corrected for body mass index SDS. Repeated measurements analysis showed a significant positive association between IGF-I SDS and total body and lumbar spine BMDSDS, but not with BMADSDS.

Conclusions: Our results show that prepubertal children with PWS have a normal BMD. GH treatment had no effect on BMD, except for a temporary decrease of total body BMDSDS in the first 6 months.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2009 by The Endocrine Society